Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes
复制标题
DOI：
10.1016/j.leukres.2012.04.025
复制
发表时间：
2012-09-01
影响因子：
2.7
通讯作者：
Nimer, Stephen D.
中科院分区：
文献类型：
--
作者：
Klimek, Virginia M.;Dolezal, Emily K.;Nimer, Stephen D.
我们回顾性评估了在纪念斯隆-凯特琳癌症中心治疗的 42 名成人治疗相关骨髓增生异常综合征 (tMDS) 患者队列以及 2 个行业赞助的地西他滨试验（D0007 和 DACO-020）中对 5-氮杂胞苷和地西他滨的形态学和细胞遗传学反应。总缓解率（完全缓解+骨髓CR+血液学改善）为38%，其中完全缓解6例（14%），骨髓CR伴或不伴血液学改善6例（14%），仅血液学改善4例（10%）。我们得出结论，DNA 甲基转移酶抑制剂在 tMDS 中表现出的活性与在 de novo MDS 中观察到的活性大致相当。 (c) 2012 Elsevier Ltd. 保留所有权利。
We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission + marrow CR + hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS. (c) 2012 Elsevier Ltd. All rights reserved.